Navigation Links
Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients

Broadest, Most Comprehensive Survey Provides New Benchmark on MRSA in Healthcare Facilities

WASHINGTON, June 21, 2007 /PRNewswire-USNewswire/ -- The following was released today by APIC:

    WHAT:


    -- First nationwide study of the prevalence of Methicillin-resistant

       Staphylococcus aureus (MRSA), a virulent multi-drug resistant organism,

       in U.S. healthcare facilities.


    -- MRSA prevalence study findings significantly exceed previous estimates

       and will for the first time provide a picture of the threat MRSA poses

       to patients in facilities caring for virtually every type of patient,

       including acute care, cancer, cardiac, pediatric, rehabilitation and

       long-term care.


    -- The study, funded by the Association for Professionals in Infection

       Control and Epidemiology (APIC), collected data from more than 1,200

       healthcare facilities in all 50 states to determine the current

       magnitude of MRSA.


    -- Results and implications from the study on MRSA will be discussed at

       APIC's 34th Annual Conference & International Meeting.


    WHEN/WHERE:


      12:00 p.m. Eastern, 9:00 a.m. Pacific, Tuesday, June 26, 2007

      San Jose, CA     Marriott, Guadalupe Room

      301 South Market Street (Directions,

      http://www.apic.org/scriptcontent/custom/sites/ac2007/index.cfm)

                  or

      Media call-in connection: 800-308-9694, enter 400179

      For study results, please go to: http://www.apic.org/MRSAStudy (link

      will be live at 12:01 am, 6/25/07)


    WHY:


    -- In 1972, MRSA accounted for only two percent of all Staphylococcus

       aureus healthcare-associated infections (HAIs) reported to the Centers

       for Disease Control and Prevention (CDC). Today, MRSA accounts for more

    
   than 60 percent of Staphylococcus aureus infections.


    -- The MRSA death rate has been estimated to be more than 2.5 times higher

       than infections from Staphylococcus aureus that are susceptible to

       methicillin.


    -- While there are a few national MRSA estimates, these are limited in

       scope and size, and therefore, the true magnitude of the total burden

       of MRSA in the U.S. healthcare population is unknown.


    WHO:


    -- Kathy Warye -- Chief Executive Officer, APIC

    -- Denise Murphy, RN, MPH, CIC -- 2007 APIC President

    -- William Jarvis, M.D. -- President, Jason and Jarvis Associates


    CONTACT:


    Journalists wishing to participate in the press briefing in person or via

    telephone and/or arrange interviews please call Jonathan Osmundsen at

    202-261-2869, email: .

Jonathan.Osmundsen@mslpr.com

CONTACT: Jonathan Osmundsen, +1-202-261-2869,, for APIC Jonathan.Osmundsen@mslpr.com

Web site: http://www.apic.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
2. First-of-its-Kind National Report Reveals Estimated High Prevalence and Heavy Cost of Type 2 Diabetes Complications in America
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... MARIETTA, Ga., Feb. 23, 2017  MiMedx Group, Inc. ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of ... quarter and full year ended December 31, 2016. ... Revenue is a 31% increase over full year ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Cardiac Prosthetic ... 9.2% over the next decade to reach approximately $8.9 billion by ... forecasts for all the given segments on global as well as ...
(Date:2/23/2017)... 23, 2017  Spheryx, Inc. will present ... at PittCon 2017 Conference and Exposition at ... world,s largest annual premier conference and exposition ... array of industry, academic and government communities ... food safety, environmental, bioterrorism and other emerging ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... Thomas Vas-Don suffered from severe injury due ... was able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ... the principals of massage, anatomy , trigger points and referral pain patterns ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Gevir, a ... deer antler velvet, announced its products are coming soon to Amazon.com, the world’s largest ... Shelley Thomson as a means to develop an effective natural treatment for Shelley’s Multiple ...
(Date:2/22/2017)... ... , ... The National Academy of Certified Care Managers (NACCM) ... testing period. NACCM, a nonprofit organization, has provided the premier certification for Care ... re-calibrated to ensure that newly certified professionals are prepared to work effectively on ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... with chronic conditions reported skipping doses or not filling a prescription because they ... under-insured, rates of cost-related problems getting medications were 30-60%*. At the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
Breaking Medicine News(10 mins):